Breast Cancer Clinical Trials
A Phase 3 study where men and postmenopausal women with breast cancer are randomly assigned to one of two categories, and neither patients nor their treating physicians will know which category will be assigned to the patient: 1) the study drug alpelisib in combination with fulvestrant, or 2) placebo in combination with fulvestrant (CBYL719C2301).
- Patients must be hormone receptor-positive.
- Patients must be HER2-negative.
- Patients must have advanced breast cancer which has progressed while on, or after receiving treatment with letrozole, anastrozole, or exemestane.
A Phase 3b study to assess ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease (“CompLEEment-1” CLEE011A2404).
- Patients must be male or female with advanced breast cancer recurring in the chest area, or that has metastasized to other areas, and is not suitable for surgical removal.
- emale patients may be pre/perimenopausal, or postmenopausal. However, menopausal status will be assessed. Men and premenopausal women will be given goserelin (suppresses sex hormone).
- Patients must have a confirmed diagnosis of estrogen-receptor positive, and/or progesterone receptor positive breast cancer.
SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy
The main purpose of this study is to learn whether cancer cell growth (disease progression) is delayed in people taking seribantumab and fulvestrant for the treatment of heregulin positive, hormone receptor positive metastatic breast cancer.
SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment
The purpose of this study is to determine whether treatment with alpelisib plus fulvestrant prolongs progression-free survival compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer, who received prior treatment with an Aromatase Inhibitor either as (neo)adjuvant or for advanced disease.
COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib
The purpose of this Phase IIIb study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast canc
(LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
BYlieve: A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment (BYLieve)
Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or fulvestrant
Madeline: Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer
POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study
This non-interventional study seeks to describe and analyze the clinical use of palbociclib in routine clinical practice in the treatment of advanced breast cancer by observing prescribing and treatment patterns in routine clinical practice in Advanced Breast Cancer (ABC) treatment, Metastatic Breast Cancer (MBC) treatment sequence, and patient quality of life.
Schedule a Consultation Today!
Your health is important, and we welcome the opportunity to help you heal.
To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or use our interactive Online Appointment Request Form.